Slide 1: Merck Oncology Overview AACR 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
Slide 2: Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These
Slide 3: Merck Oncology
MERCK ONCOLOGY Establish KEYTRUDA as A LEADER IN foundational treatment in monotherapy and in DELIVERING combination across multiple tumor Identify BREAKTHROUGH types and stages of disease APPROACHES THAT EXTEND AND Explore combinations and Identify patients most likely to IMPROVE THE other novel ag
Slide 4: Significant Progress in Oncology Over Last Few Years
SIGNIFICANT PROGRESS IN ONCOLOGY OVER LAST FEW YEARS Assets under collaboration with our partners ~ 60 LEADERS IN DELIVERING BREAKTHROUGH Approximate INNOVATIONS 700+ THAT EXTEND ~200K AND Clinical trials studying over IMPROVES number of patients treated worldwide THE LIVES OF PEOPLE WITH CANCER wit
Slide 5: KEYTRUDA demonstrated anti-tumor activity in more than 25 cancer types
KEYTRUDA DEMONSTRATED ANTI-TUMOR ACTIVITY IN MORE THAN 25 CANCER TYPES approved - - - under review 1. Daud A et al. ASCO 2015; 2. Garon EB et al. ESMO 2014; 3. Seiwert T et al. ASCO 2015; 4. Plimack E et al. ASCO 2015; 5. Nanda R et al. SABCS 2014; 6. Bang YJ et al. ASCO 2015 ; 7. Moskowitz C et al.
Slide 6: KEYTRUDA: Building Momentum
KEYTRUDA: BUILDING MOMENTUM 10 APPROVED INDICATIONS Esophageal Renal EXECUTING ON Ovarian WAVE 2 & 3 WITH Cervical* Head and Neck Bladder Prostate CONTINUED Gastric Non-Hodgkin Lymphoma* Hepatocellular PROGRESS TNBC Colorectal Other Thoracic Malignancies Melanoma Hodgkin Lymphoma Gynecolog
Slide 7: Expanding Our Oncology Portfolio Through Global Strategic Collaborations
EXPANDING OUR ONCOLOGY PORTFOLIO THROUGH GLOBAL STRATEGIC COLLABORATIONS LEADERS IN DELIVERING BREAKTHROUGH INNOVATIONS THAT EXTEND AND IMPROVES • THE LIVES Best-in-class PARP inhibitorOF and first PEOPLE PARP in breast cancer WITH CANCER • Significant long-term opportunity across multiple tumors an
Slide 8: Exploring 20+ Assets in Oncology Pipeline
EXPLORING 20+ ASSETS IN ONCOLOGY PIPELINE STING Cavatak Immune Agonists RIG-I Other Agonists GITR Oncolytic Viruses IL-10 IDO+TDO, TDO LAG-3 CTLA-4 Nab Negative Immune TIGIT Multi-Specific Nabs Regulators IDO CXCR2 Preclinical Programs CTLA-4 Clinical Programs Personalized Cancer RNA-based vaccines
Slide 9: KEYNOTE-189 and KEYNOTE-054: Data to Highlight at AACR 2018
KEYNOTE-054: Pembrolizumab versus placebo after complete resection of high- AACR 2018 Melanoma risk stage III melanoma KEYNOTE-189 KEYNOTE-054 DATA TO Randomized, Double-Blind, Phase 3 Pembrolizumab versus placebo after HIGHLIGHT Study of Pembrolizumab or Placebo plus complete resection of high-risk
Slide 10: KEYNOTE-189
KEYNOTE-189 KEYTRUDA PHASE 3 TRIAL COMBINING KEYTRUDA AND CHEMOTHERAPY REDUCED THE RISK OF DEATH Pembro/Pem/Plat Events 31.0% HR (95% CI) 0.49 P <0.00001 BY HALF OS 100 Placebo/Pem/Plat 52.4% (0.38-0.64) COMPARED TO CHEMOTHERAPY 90 HR=0.49 80 [all comers] 70 60 ALONE OS, % 50 40 KEYTRUDA is the 30 f
Slide 11: KEYNOTE-189: OS Benefit Across All PD-L1 Subgroups
KEYNOTE-189 OS BENEFIT ACROSS ALL PD-L1 SUBGROUPS OVERALL SURVIVAL IS THE GOLD STANDARD TPS <1% TPS 1-49% TPS ≥50% SETS THE BAR HR HR HR Events (95% CI) Pa Events (95% CI) Pa Events (95% CI) Pa Pembro/Pem/Plat 38.6% 0.59 0.0095 28.9% 0.55 0.0081 25.8% 0.42 0.0001 Placebo/Pem/Plat 100 55.6% (0.38-0.9
Slide 12: KEYNOTE-189 and KEYNOTE-054: Data to Highlight at AACR 2018
KEYNOTE-054: Pembrolizumab versus placebo after complete resection of high- AACR 2018 Melanoma risk stage III melanoma KEYNOTE-189 KEYNOTE-054 DATA TO Randomized, Double-Blind, Phase 3 Pembrolizumab versus placebo after HIGHLIGHT Study of Pembrolizumab or Placebo plus complete resection of high-risk
Slide 13: KEYNOTE-054
KEYNOTE-054 PHASE 3 TRIAL STUDYING KEYTRUDA IN DATA ADJUVANT MELANOMA DEMONSTRATE PROLONGED RECURRENCE FREE SURVIVAL HR=0.57 (RFS) BENEFIT 43% reduction in risk of recurrence or death regardless of disease stage, PD-L1 expression or mutation status 13
Slide 14: What to Watch: Key Data Read-Outs Over the Next Months
WHAT TO WATCH: KEY DATA READ-OUTS OVER THE NEXT 18 MONTHS Research & Development • 1L NSCLC PD-L1 > 1%: KEYNOTE-042 • 2L HCC: KEYNOTE-224 • 1L SQ NSCLC COMBO: KEYNOTE-407 • 1L H&N MONO/COMBO: KEYNOTE-048 • 1L TNBC: KEYNOTE-522 • 2L+ TNBC: KEYNOTE-119 • cHL: KEYNOTE-204 • 1L GASTRIC MONO/COMBO: KEYNO
Slide 15: Q&A
Q&A 15